日本人2型糖尿病症例にてエンパグリフロジンの臨床的有用性を検証した。外来通院中52症例においてエンパグリフロジン10mg/日を投与3ヵ月間内服にて体重の2.27kgの減少を認めるとともに随時血糖値の59.4mg/dLの低下，HbA1cの0.84％改善が確認された。これとともに，収縮期および拡張期血圧の改善を認め，血中HDL-C値の増加，中性脂肪値の低下，脂肪肝による肝機能異常や高尿酸血症の改善や尿中アルブミン尿の改善が観察された。エンパグリフロジンは，血糖管理の改善のみならず，体重減少とともに肥満症に伴う各合併症についても総合的に改善する可能性が示唆された。

   We evaluated clinical usefulness of empagliflozin in 52 Japanese outpatients with type 2 diabetes mellitus. Empagliflozin (10 mg/day) administration for 3 months significantly decreased body weight by 2.94 ％ and reduced HbA1c by 0.84 ％. Empagliflozin also significantly reduced both systolic and diastolic blood pressures, and improved hypertriglyceridemia and low HDL-cholestrolemia. Empagliflozin ameliorated liver dysfunction associated with non-alcoholic fatty liver disease as well. In addition, serum uric acid levels were decreased by empagliflozin. Furthermore, empagliflozin treatment for 3 months reduced albuminuria. In conclusion, empagliflozin not only improved glycemic control, but also ameliorated obesity-associated metabolic risks in patients with type 2 diabetes mellitus.